Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment

Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing–remitting multiple sclerosis. Several clinical trials have shown consistent and sustained efficacy of glatiramer acetate 20 mg subcutaneously daily in...

Descripción completa

Detalles Bibliográficos
Autores principales: Caporro, Matteo, Disanto, Giulio, Gobbi, Claudio, Zecca, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144933/
https://www.ncbi.nlm.nih.gov/pubmed/25170258
http://dx.doi.org/10.2147/PPA.S68698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144933/
https://www.ncbi.nlm.nih.gov/pubmed/25170258
http://dx.doi.org/10.2147/PPA.S68698

Ejemplares similares